Perlecan Domain V Stroke Recovery via Integrin Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current experimental stroke therapies, including pharmaceuticals and stem cell treatments, pose significant risks and have limitations such as systemic side effects, uncertain cell distribution, and timing-dependent consequences, while growth factors like VEGF can exacerbate early stroke pathology but offer neuroprotection later.
Innovation Solution
The use of perlecan domain V (DV), a naturally occurring extracellular matrix fragment, which is neuroprotective, targets stroked and peri-infarct brain tissue, enhancing angiogenesis and motor function recovery by interacting with the α5β1 integrin and releasing vascular endothelial growth factor, even when administered 24 hours after stroke.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If growth factors like VEGF are used for neuroprotection, then motor function recovery is improved, but early stroke pathology is exacerbated
Solution Approach 1:
The perlecan protein is segmented into functional domains (specifically domain V is used), allowing selective activation of beneficial effects while avoiding harmful early-phase actions. This segmentation enables the therapeutic to provide neuroprotection and promote angiogenesis without exacerbating early stroke pathology.
Solution Approach 2:
The patent demonstrates that perlecan domain V can be administered up to 24 hours after stroke onset, performing protective actions before the full expression of harmful stroke pathways occurs. This preliminary action prevents secondary injury and promotes recovery without interfering with acute thrombolysis or early vascular responses.
2Reliability
If stem cell therapy is used for stroke treatment, then tissue repair is enhanced, but significant risks and unacceptable side effects occur
Solution Approach 1:
The patent extracts and utilizes specific functional domains (domain V) of perlecan that are responsible for neuroprotection and angiogenesis, separating these beneficial functions from the complex, risky stem cell therapy system. This extraction provides a purified therapeutic mechanism with well-defined safety profile.
Solution Approach 2:
Perlecan domain V serves as a small, safe, and readily administrable therapeutic molecule compared to complex stem cell therapies. It provides immediate and sustained benefits without the long-term uncertainties and safety concerns associated with stem cell transplantation.
3Reliability
If pharmaceutical therapies are used for acute stroke treatment, then immediate neuroprotection is achieved, but timing-dependent consequences and systemic side effects occur
Solution Approach 1:
Perlecan domain V exhibits selective targeting of the ischemic brain region through interaction with α5β1 integrin, which is upregulated in stroke-affected tissue. This local quality allows the therapy to provide neuroprotection specifically at the site of injury without causing systemic side effects associated with broad-spectrum pharmaceuticals.
Solution Approach 2:
The patent identifies and exploits changes in integrin expression parameters (upregulation of α5β1) that occur specifically in stroke-affected tissue. By targeting this parameter change, the therapy achieves timing-independent efficacy, working effectively whether administered early or up to 24 hours after stroke onset.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DV is well-tolerated, effectively reduces ischemic lesion size, improves motor function to pre-stroke levels, and promotes angiogenesis without early adverse effects, demonstrating a distinct and safe therapeutic approach for stroke recovery.
Implementation Method 1
exerts its beneficial effect via a previously unreported mechanism of upregulation of and interaction with the α5β1 integrin and subsequent release of vascular endothelial growth factor
Implementation Method 2
via a previously unreported mechanism of upregulation of and interaction with the α5β1 integrin and subsequent release of vascular endothelial growth factor
Data Source
Figure 1A~1D
Figure 1E~1F
Figure 2A~2F
AI summary
The disclosed invention relates to the use of perlecan domain V (DV) for the treatment of stroke, traumatic brain injury (TBI) or spinal cord injuries (SCI). In certain embodiments, fusion proteins of DV can be used for the treatment of stroke, TBI or SCI. DV is also referred to as endorepellin in the art. This application also provides compositions and combination therapies for the treatment of stroke, TCI and/or SCI. Another aspect of the invention provides methods of restoring motor function in subjects having neurological damage arising from a stroke, TBI or SCI.